Skip to main content

Table 1 Baseline characteristics

From: Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function

Characteristic

Value (n = 90)

Age (yr)

56.0 ± 10.3

Hypertension

66 (73.3)

 Well-controlled (BP < 140/90 mmHg)

39 (43.3)

 Uncontrolled (BP ≥ 140/90 mmHg)

27 (30.0)

Smoking

57 (63.3)

 Ex-smoker

30 (33.3)

 Current smoker

27 (30.0)

Insulin

20 (22.2)

Dyslipidemia

79 (87.8)

Obesity (BMI ≥ 30 kg/m2)

73 (81.1)

No. of risk factors

 ≥ 3

78 (86.7)

 ≥ 4

58 (64.4)

 ≥ 5

29 (32.2)

Medication

 Calcium channel blocker

21 (23.3)

 β-blocker

3 (3.33)

 ARB/ACEi

59 (43.3)

 Statin

68 (75.6)

 Antithrombotic agent

27 (30.0)

 Dipeptidyl peptidase-4 inhibitor

64 (71.1)

 Metformin

86 (95.5)

 Sulfonylurea

36 (40.0)

 Thiazolidinedione

1 (1.11)

 Insulin

20 (22.2)

  1. Values are presented as mean ± standard deviation or number (%)
  2. BP blood pressure, BMI body mass index, ARB angiotensin receptor blocker, ACEi angiotensin converting enzyme inhibitor